During early drug developments, meeting delivery deadlines takes higher priority than process optimization. As a drug candidate moves forward in developmental phases, production at increasing quantity demands for optimized processes meeting multi-dimensional constraints, such as cost, safety, environmental, regulatory, etc..

• Optimize via Quality by Design (QbD)

    The best approach to quality assurance in pharmaceutical manufacturing is to design and control processes based on

    fundamental understanding  of underlining sciences and technologies. We optimize crystallization processes based on

    QbD principles and strive for high quality standards.

•  Enhance Processing Efficiency

    Processing efficiency is critical to pharmaceutical manufactures, and a focus of our crystallization process development.

    We optimize for high processing efficiency 　considering various aspects, such as time, volume, material, wastes, etc..

Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.

Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.

Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.